Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course radiotherapy plus CAPOX and bevacizumab followed by resection in primary metastatic rectal cancer
NL-OMON27950Phase 2Active, not recruiting
- Sponsor
- K. Havenga, M.D. Ph.D.
- Start
- Apr 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, capecitabine and oxaliplatin in rectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC), sponsored by K. Havenga, M.D. Ph.D. Primary endpoint: R0 resection or ablation rate of all tumor sites. Started Apr 2006; status: active, not recruiting.
02
Drugs
bevacizumabcapecitabineoxaliplatin
03
Conditions
rectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON27950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27950.